Abstract
PURPOSE: This prospective study is one of the first
worldwide to examine uptake and implications of
genetic testing for melanoma risk in a sample of highrisk
families with identified family-specific mutations.
METHODS: Families comprising three or more
relatives with a confirmed melanoma diagnosis were
ascertained via the Westmead Institute for Cancer
Research/University of Sydney centre of the Genetic
Epidemiology of Melanoma Study. Eligibility criteria
included identification of a family-specific mutation
in the CDKN2A gene via the research protocol, and no
previous genetic testing for clinical purposes. A series
of mailed, self-report questionnaires were used to
collect data at: notification of genetic test availability
(January 2005), and two weeks and 12 months after
receipt of genetic test results (for ‘test takers’), or 12
months after notification (for ‘test decliners’).
RESULTS: 121 eligible individuals (48% male)
returned baseline questionnaires, yielding a response
rate of 72%. At baseline, mean psychological distress
scores were relatively low. Factors associated with
distress included: having a personal history of
melanoma (OR=3.37, p=0.03), perceiving greater
family-related consequences of melanoma (OR=2.52,
p<0.0001), and displaying a tendency to monitor for
risk-relevant information (OR=3.12, p=0.01). As of
January 2008, 25 participants had undergone genetic
testing, with 75% of those who had received results
identified as mutation carriers. Preliminary analyses
show that at baseline, test takers reported significantly
higher levels of distress compared to decliners (Z=-
2.27, p=0.02). Further, carriers reported significantly
reduced depression scores two weeks after receipt of a
positive result (Z=-2.25, p=0.02). CONCLUSION:
Distress was relatively uncommon in this familial
melanoma cohort, even after notification of the
presence of a family mutation and receipt of positive
genetic test results. RESEARCH IMPLICATIONS: It
is pertinent to examine low levels of genetic testing
uptake in the context of attitudes toward testing,
health-related behaviours, and testing availability.
CLINICAL IMPLICATIONS: Given the association
between distress and perceived family-related
consequences of melanoma, it is imperative that
clinicians communicate genetic risk information in
ways that relate meaningfully to the illness
experiences of both individuals and their families.
ACKNOWLEDGEMENT OF FUNDING: N.
Kasparian is supported by an NH&MRC Clinical
Research Australia Fellowship. This project is also
supported by a Cancer Council NSW Strategic
Research Partnership Grant and a Cancer Institute
NSW Program Grant for Excellence in Translational
Research.
Original language | English |
---|---|
Article number | P2-109 |
Pages (from-to) | S277-S278 |
Number of pages | 2 |
Journal | Psycho-Oncology |
Volume | 17 |
Issue number | Supplement S2 |
Publication status | Published - Jun 2008 |
Externally published | Yes |
Event | International Psycho-Oncology Society (IPOS) 10th World Congress of Psycho-Oncology: IPOS - Madrid, Spain Duration: 9 Jun 2008 → 13 Jun 2008 |